Современные хирургические стратегии лечения метастатического колоректального рака (обзор литературы)

Кит Олег Иванович; Геворкян Юрий Артушевич; Солдаткина Наталья Васильевна; Колесников Владимир Евгеньевич; Бондаренко Ольга Константиновна; Дашков Андрей Владимирович

��-�� . 2024. �. 5, � 3. �. 102-110

https://doi.org/10.37748/2686-9039-2024-5-3-9

https://elibrary.ru/lxyray

3.1.6. ��, ��

��

�� ..

�� (�� )..

�. �. ��, �. �. ��, �. �. �� , �. �. ��, �. �. ��, �. �. ��

�� , �.

��-��-��, ��

snv-rnioi@yandex.ru

��

�� 50�60

% �� (��). � ��

��

�� . � ��

�� .

� �� (�� PubMed, Scopus,

eLIBRARY) � ��

�� .

� �� :

�� (��

� ��

��, tumour burden, �� RAS, BRAF),

�� (��,

performance status,

��

� ��,

��,

��

�� , �� ) � �� (��, ��

��, ��

��, �� ). ��

��

�� , � ��

� ��, �� , ��

�

��

�

��

��.

��

�� , ��

��

�� , �� , �� , �� .

�� /��

��, ��

��

��. ��

�� , �� . ��

� �� .

��

��: ��, �� , �� , ��, ��

�� : �� . �., �� . �., �� . �., �� . �., �� . �., �� . �. ��

�� (�� ). ��- �� . 2024; 5(3):102-110.

https://doi.org/10.37748/2686-9039-2024-5-3-9, https://elibrary.ru/lxyray

�� :

��

��. �. �., �� , ��

�� , �. ��-��- ��, ��

��

��: 344037, �� , �. ��-��- ��, ��. 14-� ��, �. 63

E-mail: snv-rnioi@yandex.ru

ORCID: https://orcid.org/0000-0002-0118-4935

SPIN: 8392-6679, AuthorID: 440046, Scopus Author ID: 23499757500

��:

��

�� :

�� . �., �� . �. �� - ��

� 2019 �., �� . �� .

��

�� 06.06.2023; �� 01.06.2024; �� 19.06.2024

� �� . �., �� . �., �� . �., �� . �., �� . �., �� . �., 2024

South Russian Journal of Cancer. 2024. Vol. 5, No. 3. P. 102-110

https://doi.org/10.37748/2686-9039-2024-5-3-9

https://elibrary.ru/lxyray

REVIEW

Modern strategy of metastatic colorectal cancer treatment (literature review)..

O.

I. Kit, Yu. A. Gevorkyan, N. V. Soldatkina , V. E. Kolesnikov, O. K. Bondarenko, A. V. Dashkov

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

snv-rnioi@yandex.ru

ABSTRACT

Metastatic lesions

account for about 50�60 % of all cases of colorectal cancer (CRC). Currently, the prognosis for metastatic

CRC has significantly improved due to the advent of effective drug therapy and the expansion of surgical treatment options.

In this regard, the study of modern directions of treatment of metastatic CRC is of particular interest.

In this study, both literature data and obtained treatment results of patients with metastatic colorectal cancer have been

analyzed (PubMed, Scopus, eLibrary databases were used) at the National Medical Research Centre for Oncology.

Currently, many factors should be taken into account when planning therapy for patients with metastatic CRC: the characteristics

of the tumor

itself (biology and localization of the tumor, tumor burden, RAS, BRAF mutational status), the patient (age,

performance status, functional state of organs and systems, comorbidity, patient attitude, expectations and preferences) and

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

the treatment itself (toxicity, flexibility of the treatment program, socio-economic factors, quality of life). With a resectable

process, surgical treatment with adjuvant or perioperative chemotherapy, and with potentially resectable liver metastases,

with massive prevalence, unfavorable prognosis � to carry out the most active drug therapy taking into account the mutational

status of the tumor in order to transfer the process to a resectable

one. In case of widespread colorectal cancer, drug

therapy lines are consistently carried out, the selection of which is based on the goals of therapy, the type and time of primary

therapy, the mutation profile of the tumor, and the toxicity of drugs.

Patients with metastatic liver and/or lung lesions should be considered through the prism of surgical treatment, since it is

surgical intervention that can significantly improve the results of treatment of patients. Therefore, patients with potentially

resectable metastases should receive the most effective treatment and be operated on as soon as the process becomes

resectable. At the same time, modern chemotherapy and targeted therapy are an integral part of the treatment of patients

with metastatic colorectal cancer.

Keywords: review, metastatic colorectal cancer, liver resection, chemotherapy, targeted therapy

For citation: Kit O. I., Gevorkyan Yu. A., Soldatkina N. V., Kolesnikov V. E., Bondarenko O. K., Dashkov A. V. Modern strategy of metastatic colorectal cancer

treatment (literature review). South Russian Journal of Cancer. 2024; 5(3): 102-110. (In Russ.). https://doi.org/10.37748/2686-9039-2024-5-3-9,

https://elibrary.ru/lxyray

For correspondence: Natalya V. Soldatkina � Dr. Sci. (Med.), MD, leading researcher of the Department of General Oncology, National Medical Research

Centre for Oncology, Rostov-on-Don, Russian Federation

Address: 63 14 line str., Rostov-on-Don 344037, Russian Federation

E-mail: snv-rnioi@yandex.ru

ORCID: https://orcid.org/0000-0002-0118-4935

SPIN: 8392-6679, AuthorID: 440046, Scopus Author ID: 23499757500

Funding: this work was not funded

Conflict of interest: Kit O. I. and Soldatkina N. V., have been the members of the editorial board of the South Russian Journal of Cancer since 2019, however

they have no relation to the decision made upon publishing this article. The article has passed the review procedure accepted by the journal. The authors did

not declare any other conflict of interest

The article was submitted 06.06.2023; approved after reviewing 01.06.2024; accepted for publication 19.06.2024

South Russian Journal of Cancer 2024. Vol. 5, No. 3. P. 102-110

Kit O. I., Gevorkyan Yu. A., Soldatkina N. V. , Kolesnikov V. E., Bondarenko O. K., Dashkov A. V. Modern strategy of metastatic colorectal cancer treatment

(literature review)

��

�� (��)

��

�� [1, 2]. �

��

�� 2022 �. �� 124 �� 100 ��. ��

[3].

��

�

50�60

%

��

��,

��

�� 20�50

%, � ��

��

15�30

% ��, �

��

� ��

��

[4, 5]. ��

��

�� , ��

��, ��

� ��

��

��.

��

��, ��

(40

%), �� 25

%

��

��. � 30

%

��

�� 1/3 �� . �

70

%

��

� ��

��

[6,

7].

��

�

��,

��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

��

�� ,

�, � ��, �� .

��

��, � ��

��

�� , ��

� ��

��

�� [8, 9].

�� : ��

�� .

��

��.

��

� �� (��

��, ��

�� ), � ��

��

(��

��,

��).

��

FOLFOX

� FOLFIRI �� , ��

��

�� FOLFOX

� 1

��

�� [10]. ��

��

PRIME, ��

��

� ��

512

��, ��, ��

� ��

��

EGFR �� 60

%

��

�� R0

��

� ��

��, � ��

�� [11]. ��

��

� ��,

�� F.

Petrelli � ��. [12].

�� FIRE-3, �� 353

��, ��

��

�� , ��

��

�� ,

��

� FOLFIRI

��

3,5

��

[13]. ��

��

��,

��

RAS ��

� 1

��

+

��

[14].

��

RAS/BRAF

� ��

��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

��EGFR, ��

�

��

[15].

��

�� 5-��

��

� 9

�� 42

% [16].

��

� ��

��

� �� LiverMetSurvey

International Registry, �� 23

��.

�� 5-��

�� 42

%, ��

��

�

9

%.

� �� .

�.

Simmonds � ��. [17] ��

�� 30 ��

��,

��

5-��

��

� �� R0/R1

��

30�32

%, �� R2 � 7 %, ��

��

�

0

%. ��, �� G.

P.

Kanas

� ��. [18] ��, �� 5-��

��

�� ,

��

�� , �� 38

%. ��,

��

�� [6].

��

�� R.

Adam � ��

� �� [19]. ��

��

R0

��

�� 30

% ��

��

��, � ��

��. ��

�� R0

�� ,

��-�� 2024. �. 5, � 3. �. 102-110

��

�.

�., ��

�.

�., ��

�.

�. , ��

�.

�., ��

�.

�., ��

�.

��

� �� R1 ��.

��

��, 5

� �� , ��

��.

��

��: R1

��, ��

��,

�� 1 ��, �� 5

��, ��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

�� 200 ��/��, ��

��, ��c��

12

��., �� [16, 19],

�� BRAF [20].

��

� ��

��. ��

��

�� (�� ).

��

�� - �� .

��

�� [21].

R.

Adam

��

�� : ��

��

�

��

�

��

��,

��

��, �� , ��

�

�� , � ��

�� ; ��

� ��

�� , ��

� �� . ��

��

��.

��

��, ��

��

�� [7].

F.

Aigner � ��. ��

� �� : ��

��

�� , � ��

�� [22].

�� (�� )

��

�� , ��

��

(��, ��)

�

�� (� ��

�� RAS) � ��

�� [11, 23].

��

� ��

�� , ��

��

�� ,

��

��,

��

��.

��

�� .

��-��, 83

% ��

��

��,

��-��,

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

��

�� [18, 22], ��

��

�� 2�3

�� [24].

�� , ��

��

��: 13,6

%

�

�� ,

19

%

�

�� 5

�� , 45,4

%

�

�� 6�9

�� , 61,5

%

�

��

10

� ��

��

�� [25, 26]. ��

(. 20

% �� . 30

%)

�� 6�8

��

� ��

��

�� [11, 27].

��

�� . ��

��

� ��

��.

��

�

��

� ��

��. ��

��

� ��

��

�� [28].

�

2019

�. ��

��

18

��,

�� 7081 ��, ��

��

South Russian Journal of Cancer 2024. Vol. 5, No. 3. P. 102-110

Kit O. I., Gevorkyan Yu. A., Soldatkina N. V. , Kolesnikov V. E., Bondarenko O. K., Dashkov A. V. Modern strategy of metastatic colorectal cancer treatment

(literature review)

�� [29]. ��, ��

��

��, �� ,

��

��. � ��

��

�� 12

��,

�� 2505 �� [30].

� ��

� � �� . ��,

N.

Kokudo

[31] ��

��

� ��

�� 2

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

% ��

� ��

5

��

� ��

��. �� , ��

��

�� 1

��. �� 1

��

�

��, � 5-��

��

33

% [31]. ��

��, ��

�� R1

��

�� [32].

��

� ��

��

�� [33�35].

��

��,

��

�� . ��

��

�� ,

� ��, � ��

T.

Schmidt

[36], � ��

��

578

��

��,

��

�� 5-��

�� 36,7

%, ��

��

�

56,6

%, ��

�

53,2

%.

��

�� ,

�� pT-��

� �� [37]. ��

7200

��

27

�� , ��

��

�� , ��, ��

��

[36].

��, ��

�� .

�

��

�� ,

��

��, �� , ��

��

45,6

�� 40,5

��

�� [38].

��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

�

��

��. ��

��

M.

W.

Onaitis � ��. [39],

�

��

28

% 3-�� 78

% ��

�� 378 ��. ��

��

� ��

��: �� ,

�� ,

��

1

�� , ��

�� , �� R1, ��

��

��,

��

�

��

[39, 40].

��

� ��

�� [39].

��

� ��

��

� ��

�� [41].

��

�� , ��

��

� �� , ��

�� 24

% ��. ��

��

� �� , ��

� ��, � ��

�� 23 �� [42].

��

�� ESMO-ASIA 2019

�. ��

��

� ��

��

� ��

��

��,

� ��

��

��-�� 2024. �. 5, � 3. �. 102-110

��

�.

�., ��

�.

�., ��

�.

�. , ��

�.

�., ��

�.

�., ��

�.

��

�� (�� )

�� ,

�� , ��

��

�

��

� ��

��

[21]. ��

��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

��

��, �� ,

�� , ��

�� , �� . � ��

��

�� (��/��, ��,

��) �� [43].

��

�� . ��

�� (�� ,

tumour burden, �� RAS, BRAF), �� (��,

�� ,

��, �� , ��

� ��) � �� (��, ��

�� , �� ,

�� ) [21]. ��

��

��, � ��

�� ASCO

2020.

��

��, ��

�� /��

�� , ��

��

��.

��

� ��, ��

�� . ��

��

� ��

��

�� .

��

1.

World Health Organization: international agency for research on cancer [Internet]. �� : https://gco.iarc.fr/today/

en/dataviz/tables?mode=population&cancers=41,

��

21.05.2024.

2.

�� . �., �� . �., �� . �., �� . �. �� : ��

��. �� . 2021;12(4(48)):52�59. EDN: CMPKOS

3.

�� 2022

�� (�� ). ��

��. �. �. ��,

�.

��,

�.

��,

�.

��.

�.:

��

��.

�.

��

.

��

� �� , 2023, 275 �.

4.

�� . �., �� . �., �� . �., �� . �. �� : ��, ��,

��-�� (�� ).

��. 2023;22(2(84)):160.171. https://doi.org/10.33878/2073-7556-2023-22-2-160-171, EDN: TWZBRV

5.

��

�� 2022

��. ��

��. �.

�.

��, �.

�.

��,

�.

��. �.: ��

��. �.

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

�.

��

�

��

��,

2022,

239

�.

6.

Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment

of patients with colorectal liver metastases. Eur J Cancer. 2006 Sep;42(14):2212�2221.

https://doi.org/10.1016/j.ejca.2006.04.012

7.

Adam

R,

de

Gramont

A,

Figueras

J,

Kokudo

N,

Kunstlinger

F,

Loyer

E,

et

al.

Managing

synchronous

liver

metastases

from

colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015 Nov;41(9):729�741.

https://doi.org/10.1016/j.ctrv.2015.06.006

8.

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer

is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 1;27(22):3677�3683.

https://doi.org/10.1200/JCO.2008.20.5278

9.

�� . �., �� . �., �� . �., �� . �., �� . �., �� . �. � ��. ��

��

KRAS

�

��-��

��

�

��

��.

�� . 2014;(1-1):65�68. EDN: RTFGVV

South Russian Journal of Cancer 2024. Vol. 5, No. 3. P. 102-110

Kit O. I., Gevorkyan Yu. A., Soldatkina N. V. , Kolesnikov V. E., Bondarenko O. K., Dashkov A. V. Modern strategy of metastatic colorectal cancer treatment

(literature review)

10.

Carrato A, Abad A, Massuti B, Gravalos C, Escudero P, Longo-Munoz F, et al. First-line panitumumab plus FOLFOX4 or

FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

Eur J Cancer. 2017

Aug;81:191�202. https://doi.org/10.1016/j.ejca.2017.04.024

11.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO

consensus guidelines for the management

of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386�1422.

https://doi.org/10.1093/annonc/mdw235

12.

Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, et al. Axitinib or bevacizumab plus FOLFIRI

or modified FOLFOX-6

after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clin

Colorectal Cancer. 2013 Dec;12(4):239�247. https://doi.org/10.1016/j.clcc.2013.09.001

13.

Petrelli F, Barni S, Anti-EGFR agents for liver metastases. Resectability and outcome with anti-EGFR agents in patients

with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis. 2012

Aug;27(8):997�1004.

https://doi.org/10.1007/s00384-012-1438-2

14.

Modest DP, Denecke T, Pratschke J, Ricard I, Lang H, Bemelmans M, et al. Surgical treatment options following chemotherapy

plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Eur J Cancer. 2018

Jan;88:77�86.

https://doi.org/10.1016/j.ejca.2017.10.028

15.

Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, et al. The best strategy for RAS wild-type metastatic

colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. Crit Rev Oncol Hematol. 2018

May;125:69�77.

https://doi.org/10.1016/j.critrevonc.2018.03.003

16.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for

metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309�318.

https://doi.org/10.1097/00000658-199909000-00004

17.

Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from

colorectal cancer: a systematic review of published studies. Br J Cancer. 2006 Apr 10;94(7):982�999.

https://doi.org/10.1038/sj.bjc.6603033

18.

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal

cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283�301.

https://doi.org/10.2147/CLEP.S34285

19.

Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncosurgery approach to managing liver

metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17(10):1225�1239.

https://doi.org/10.1634/theoncologist.2012-0121

20.

Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019

Jan;3(1):50�56.

https://doi.org/10.1002/ags3.12227

21.

Tie J, Desai J. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.

Target Oncol. 2015

Jun;10(2):179�188. https://doi.org/10.1007/s11523-014-0330-0

22.

Aigner F, Pratschke J, Schmelzle M. Oligometastatic Disease in Colorectal Cancer -How to Proceed? Visc Med. 2017

Mar;33(1):23�28.

https://doi.org/10.1159/000454688

23.

Douillard

JY,

Siena

S,

Peeters

M,

Koukakis

R,

Terwey

JH,

Tabernero

J.

Impact

of

early

tumour

shrinkage

and

resection

on

outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015 Jul;51(10):1231�1242.

https://doi.org/10.1016/j.ejca.2015.03.026

24.

Van

Vledder

MG,

de

Jong

MC,

Pawlik

TM,

Schulick

RD,

Diaz

LA,

Choti

MA.

Disappearing

colorectal

liver

metastases

after

chemotherapy: should we be concerned? J Gastrointest Surg. 2010

Nov;14(11):1691�1700.

https://doi.org/10.1007/s11605-010-1348-y

25.

Choti MA. Chemotherapy-associated hepatotoxicity: do we need to be concerned? Ann Surg Oncol. 2009

Sep;16(9):2391�

2394.

https://doi.org/10.1245/s10434-009-0512-7

26.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases

downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004 Oct;240(4):644�658.

https://doi.org/10.1097/01.sla.0000141198.92114.f6

27.

Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk

of major hepatectomy for colorectal liver metastases. Ann Surg. 2006 Jan;243(1):1�7.

https://doi.org/10.1097/01.sla.0000193603.26265.c3

��-�� 2024. �. 5, � 3. �. 102-110

��

�.

�., ��

�.

�., ��

�.

�. , ��

�.

�., ��

�.

�., ��

�.

��

�� (�� )

28.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus

FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised,

open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1065�1075. https://doi.org/10.1016/S1470-2045(14)70330-4

29.

Sui CJ, Cao L, Li B, Yang JM, Wang SJ, Su X, et al. Anatomical versus nonanatomical resection of colorectal liver metastases:

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

a meta-analysis. Int J Colorectal Dis. 2012

Jul;27(7):939�946. https://doi.org/10.1007/s00384-011-1403-5

30.

Deng G, Li H,

Jia GQ, Fang D,

Tang YY, Xie J, et al. Parenchymal-sparing versus extended hepatectomy for

colorectal liver

metastases:

A systematic review and meta-analysis. Cancer

Med. 2019 Oct;8(14):6165�6175. https://doi.org/10.1002/cam4.2515

31.

Kokudo N, Miki Y, Sugai S, Yanagisawa A, Kato Y, Sakamoto Y, et al. Genetic and histological assessment of surgical margins

in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch

Surg. 2002 Jul;137(7):833�840. https://doi.org/10.1001/archsurg.137.7.833

32.

Hamady ZZR, Lodge JPA, Welsh FK, Toogood GJ, White A, John T, et al. One-millimeter cancer-free margin is curative for

colorectal liver metastases: a propensity score case-match approach. Ann Surg. 2014 Mar;259(3):543�548.

https://doi.org/10.1097/SLA.0b013e3182902b6e

33.

Ayez N, Lalmahomed ZS, Eggermont AMM, Ijzermans JNM, de Jonge J, van Montfort K, et al. Outcome of microscopic

incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol. 2012

May;19(5):1618�1627.

https://doi.org/10.1245/s10434-011-2114-4

34.

�� . �., �� . �., �� . �., �� . �., �� . �. ��

��

��.

2015;(4(54)):19�

23. EDN: UQCUTH

35.

�� . �., �� . �., �� . �., �� . �., �� . �., �� . �. � ��. ��

��

�

��

�

��

�

��.

2014;(S3(49)):65�66. EDN: UAUMQB

36.

Schmidt T, Nienhuser H, Kuna C, Klose J, Strowitzki MJ, Buchler MW, et al. Prognostic indicators lose their value with repeated

resection of colorectal liver metastases. Eur J Surg Oncol. 2018 Oct;44(10):1610�1618.

https://doi.org/10.1016/j.ejso.2018.07.051

37.

�� . �., �� . �., �� . �., �� . �. �� .

�� . �. �. ��. 2015:10(2):810�811. EDN: YPRAWC

38.

Luo

LX,

Yu ZY,

Huang

JW,

Wu H.

Selecting

patients

for

a second

hepatectomy

for

colorectal

metastases:

an

systemic

review

and meta-analysis. Eur J Surg Oncol. 2014 Sep;40(9):1036�1048. https://doi.org/10.1016/j.ejso.2014.03.012

39.

Onaitis MW, Petersen RP, Haney JC, Saltz

L, Park B, Flores R, et al. Prognostic factors for recurrence after pulmonary resection

of colorectal cancer metastases. Ann Thorac Surg. 2009 Jun;87(6):1684�1688.

https://doi.org/10.1016/j.athoracsur.2009.03.034

40.

Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in

colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013 Feb;20(2):572�579.

https://doi.org/10.1245/s10434-012-2726-3

41.

Zabaleta J, Iida T, Falcoz PE, Salah S, Jarabo JR, Correa AM, et al. Individual data meta-analysis for the study of survival

after pulmonary metastasectomy in colorectal cancer patients: A history of resected liver metastases worsens the prognosis.

Eur J Surg Oncol. 2018 Jul;44(7):1006�1012. https://doi.org/10.1016/j.ejso.2018.03.011

42.

Wiegering A, Riegel J, Wagner J, Kunzmann V, Baur J, Walles T, et al. The impact of pulmonary metastasectomy in patients

with previously resected colorectal cancer liver metastases. PLoS One. 2017;12(3):e0173933.

https://doi.org/10.1371/journal.pone.0173933

43.

Ganesh K, Shah RH, Vakiani E, Nash GM, Skottowe HP, Yaeger R, et al. Clinical and genetic determinants of ovarian metastases

from colorectal cancer. Cancer. 2017 Apr 1;123(7):1134�1143. https://doi.org/10.1002/cncr.30424

�� :

�� , �.�.�., ��, �� , ��

�� , �. ��-��-��, ��

ORCID: https://orcid.org/0000-0003-3061-6108, SPIN: 1728-0329, AuthorID: 343182, ResearcherID: U-2241-2017, Scopus Author ID: 55994103100

��

�� .�.�., ��, ��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

�� 2, ��

��

�� , �. ��-��-��, ��

ORCID: https://orcid.org/0000-0003-1957-7363, SPIN: 8643-2348, AuthorID: 711165

South Russian Journal of Cancer 2024. Vol. 5, No. 3. P. 102-110

Kit O. I., Gevorkyan Yu. A., Soldatkina N. V. , Kolesnikov V. E., Bondarenko O. K., Dashkov A. V. Modern strategy of metastatic colorectal cancer treatment

(literature review)

��

�� .�.�., ��

�� , ��

�� , �. ��-��-��, ��

ORCID: https://orcid.org/0000-0002-0118-4935, SPIN: 8392-6679, AuthorID: 440046, Scopus Author ID: 23499757500

�� .�.�., ��-�� 2, ��

�� , �. ��-��-��, ��

ORCID: https://orcid.org/0000-0002-9979-4095, SPIN: 9915-0578, AuthorID: 705852

��

�� -��

�� 2, ��

��

�� , �. ��-��-��, ��

ORCID: https://orcid.org/0000-0002-9543-4551, SPIN: 7411-8638, AuthorID: 1223821

��

�

�.�.�.,

��-��

��

�

2,

��

�� , �. ��-��-��, ��

ORCID: https://orcid.org/0000-0002-3867-4532, SPIN: 4364-9459, AuthorID: 308799

�� :

�� . �. � �� ;

�� . �. � ��;

�� . �., �� . �., �� . �., �� . �. � �� ;

�� . �. � �� , �� .

Modern strategy of metastatic colorectal cancer treatment (literature review)

Текст научной работы на тему «Современные хирургические стратегии лечения метастатического колоректального рака (обзор литературы)»